<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD11010000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q9UDY8</UniProt_ID>
  <Seq_Length>824</Seq_Length>
  <Molecule_Weight>92272</Molecule_Weight>
  <KEGG_ID>hsa:10892</KEGG_ID>
  <Orthology_ID>K07369</Orthology_ID>
  <EBI_ID>EBI-1047372</EBI_ID>
  <Function_Summary>Enhances BCL10-induced activation of NF-kappa-B. Involved in nuclear export of BCL10. Binds to TRAF6, inducing TRAF6 oligomerization and activation of its ligase activity. Has ubiquitin ligase activity. MALT1-dependent BCL10 cleavage plays an important role in T-cell antigen receptor-induced integrin adhesion.</Function_Summary>
  <Pfam_ID>PF00656:Peptidase_C14</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>1</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Paracaspase</Alias>
      <Alias>MALT lymphoma-associated translocation</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Catalysis of the reaction: ATP + ubiquitin + protein lysine = AMP + diphosphate + protein N-ubiquityllysine.</Detail>
      <Keyword>Ubiquitin-protein ligase activity</Keyword>
      <Ontology_ID>GO:0004842</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of internal, alpha-peptide bonds in a polypeptide chain by a mechanism in which the sulfhydryl group of a cysteine residue at the active center acts as a nucleophile.</Detail>
      <Keyword>Cysteine-type endopeptidase activity</Keyword>
      <Ontology_ID>GO:0004197</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of a peptide bond. A peptide bond is a covalent bond formed when the carbon atom from the carboxyl group of one amino acid shares electrons with the nitrogen atom from the amino group of a second amino acid.</Detail>
      <Keyword>Peptidase activity</Keyword>
      <Ontology_ID>GO:0008233</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Conveys a signal across a cell to trigger a change in cell function or state. A signal is a physical entity or change in state that is used to transfer information in order to trigger a response.</Detail>
      <Keyword>Signal transducer activity</Keyword>
      <Ontology_ID>GO:0004871</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>641</Position>
      <Original>Ile</Original>
      <Variation>Val</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a fungus.</Detail>
      <Keyword>Response to fungus</Keyword>
      <Ontology_ID>GO:0009620</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of T cell activation.</Detail>
      <Keyword>Positive regulation of T cell activation</Keyword>
      <Ontology_ID>GO:0050870</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by molecules of bacterial origin such as peptides derived from bacterial flagellin.</Detail>
      <Keyword>Response to molecule of bacterial origin</Keyword>
      <Ontology_ID>GO:0002237</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process of creating protein oligomers, compounds composed of a small number, usually between three and ten, of component monomers; protein oligomers may be composed of different or identical monomers. Oligomers may be formed by the polymerization of a number of monomers or the depolymerization of a large protein polymer.</Detail>
      <Keyword>Protein oligomerization</Keyword>
      <Ontology_ID>GO:0051259</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The expansion of a T cell population by cell division. Follows T cell activation.</Detail>
      <Keyword>T cell proliferation</Keyword>
      <Ontology_ID>GO:0042098</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Protein involved in ubiquitin-like modifier processing, activation, conjugation or deconjugation such as Ubl-activating enzymes (E1s), Ubl-conjugating enzymes (E2s), Ubl-protein ligases (E3s), some thiol proteases (Ubiquitin carboxyl-terminal hydrolases (UCH), Ubiquitin-specific processing proteases (UBP) and ubiquitin-like proteases) and the ubiquitin-like modifier proteins. Besides signaling proteolysis, ubiquitination for example can be a signal for trafficking, kinase activation and other nonproteolytic fates.</Detail>
      <Keyword>Ubl conjugation pathway</Keyword>
      <Ontology_ID>KW-0833</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of signaling pathways initiated by the cross-linking of an antigen receptor on a T cell.</Detail>
      <Keyword>Regulation of T cell receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0050856</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate, or extent of T cell cytokine production.</Detail>
      <Keyword>Positive regulation of T cell cytokine production</Keyword>
      <Ontology_ID>GO:0002726</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The stimulation of the activity of NF-kappaB-inducing kinase through phosphorylation at specific residues.</Detail>
      <Keyword>Activation of NF-kappaB-inducing kinase activity</Keyword>
      <Ontology_ID>GO:0007250</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of activity of the transcription factor NF-kappaB.</Detail>
      <Keyword>Positive regulation of NF-kappaB transcription factor activity</Keyword>
      <Ontology_ID>GO:0051092</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.</Detail>
      <Keyword>Innate immune response</Keyword>
      <Ontology_ID>GO:0045087</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate, or extent of interleukin-2 production.</Detail>
      <Keyword>Positive regulation of interleukin-2 production</Keyword>
      <Ontology_ID>GO:0032743</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of an I-kappaB kinase/NF-kappaB induced cascade.</Detail>
      <Keyword>Positive regulation of I-kappaB kinase/NF-kappaB cascade</Keyword>
      <Ontology_ID>GO:0043123</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The hydrolysis of proteins into smaller polypeptides and/or amino acids by cleavage of their peptide bonds.</Detail>
      <Keyword>Proteolysis</Keyword>
      <Ontology_ID>GO:0006508</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of substances out of the nucleus.</Detail>
      <Keyword>Nuclear export</Keyword>
      <Ontology_ID>GO:0051168</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the addition of ubiquitin groups to a protein.</Detail>
      <Keyword>Positive regulation of protein ubiquitination</Keyword>
      <Ontology_ID>GO:0031398</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a hemopoietic stem cell acquires the specialized features of a B-1 B cell. B-1 B cells are a distinct subset of B cells characterized as being CD5 positive, found predominantly in the peritoneum, pleural cavities, and spleen, and enriched for self-reactivity.</Detail>
      <Keyword>B-1 B cell differentiation</Keyword>
      <Ontology_ID>GO:0001923</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A series of molecular signals initiated by the cross-linking of an antigen receptor on a T cell.</Detail>
      <Keyword>T cell receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0050852</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>135</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MSLLGDPLQALPPSAAPTGPLLAPPAGATLNRLREPLLRRLSELLDQAPEGRGWRRLAELAGSRGRLRLSCLDLEQCSLKVLEPEGSPSLCLLKLMGEKGCTVTELSDFLQAMEHTEVLQLLSPPGIKITVNPESKAVLAGQFVKLCCRATGHPFVQYQWFKMNKEIPNGNTSELIFNAVHVKDAGFYVCRVNNNFTFEFSQWSQLDVCDIPESFQRSVDGVSESKLQICVEPTSQKLMPGSTLVLQCVAVGSPIPHYQWFKNELPLTHETKKLYMVPYVDLEHQGTYWCHVYNDRDSQDSKKVEIIIGRTDEAVECTEDELNNLGHPDNKEQTTDQPLAKDKVALLIGNMNYREHPKLKAPLVDVYELTNLLRQLDFKVVSLLDLTEYEMRNAVDEFLLLLDKGVYGLLYYAGHGYENFGNSFMVPVDAPNPYRSENCLCVQNILKLMQEKETGLNVFLLDMCRKRNDYDDTIPILDALKVTANIVFGYATCQGAEAFEIQHSGLANGIFMKFLKDRLLEDKKITVLLDEVAEDMGKCHLTKGKQALEIRSSLSEKRALTDPIQGTEYSAESLVRNLQWAKAHELPESMCLKFDCGVQIQLGFAAEFSNVMIIYTSIVYKPPEIIMCDAYVTDFPLDLDIDPKDANKGTPEETGSYLVSKDLPKHCLYTRLSSLQKLKEHLVFTVCLSYQYSGLEDTVEDKQEVNVGKPLIAKLDMHRGLGRKTCFQTCLMSNGPYQSSAATSGGAGHYHSLQDPFHGVYHSHPGNPSNVTPADSCHCSRTPDAFISSFAHHASCHFSRSNVPVETTDEIPFSFSDRLRISEK</Protein_Seq>
    <DNA_Seq>CGAGGCTCCGTGCCCCGCCCCCCGGGTGCCCCGCCCCTTTGCGCGGCTGGCGCGGCCAGCAGGCCAGGCTCCCCTCGGCAAACCTGTCTAATTGGGGCGGGGAGCGGAGCTTCCTCCTCTGAGGGCCGTGCCGCGCTGCCAGATTTGTTCTTCCGCCCCTGCCTCCGCGGCTCGGAGGCGAGCGGAAGGTGCCCCGGGGCCGAGGCCCGTGACGGGGCGGGCGGGAGCCCCGGCAGTCCGGGGTCGCCGGCGAGGGCCATGTCGCTGTTGGGGGACCCGCTACAGGCCCTGCCGCCCTCGGCCGCCCCCACGGGGCCGCTGCTCGCCCCTCCGGCCGGCGCGACCCTCAACCGCCTGCGGGAGCCGCTGCTGCGGAGGCTCAGCGAGCTCCTGGATCAGGCGCCCGAGGGCCGGGGCTGGAGGAGACTGGCGGAGCTGGCGGGGAGTCGCGGGCGCCTCCGCCTCAGTTGCCTAGACCTGGAGCAGTGTTCTCTTAAGGTACTGGAGCCTGAAGGAAGCCCCAGCCTGTGTCTGCTGAAGTTAATGGGTGAAAAAGGTTGCACAGTCACAGAATTGAGTGATTTCCTGCAGGCTATGGAACACACTGAAGTTCTTCAGCTTCTCAGCCCCCCAGGAATAAAGATTACTGTAAACCCAGAGTCAAAGGCAGTCTTGGCTGGACAGTTTGTGAAACTGTGTTGCCGGGCAACTGGACATCCTTTTGTTCAATATCAGTGGTTCAAAATGAATAAAGAGATTCCAAATGGAAATACATCAGAGCTTATTTTTAATGCAGTGCATGTAAAAGATGCAGGCTTTTATGTCTGTCGAGTTAATAACAATTTCACCTTTGAATTCAGCCAGTGGTCACAGCTGGATGTTTGCGACATCCCAGAGAGCTTCCAGAGAAGTGTTGATGGCGTCTCTGAATCCAAGTTGCAAATCTGTGTTGAACCAACTTCCCAAAAGCTGATGCCAGGCAGCACATTGGTTTTACAGTGTGTTGCTGTTGGAAGCCCTATTCCTCACTACCAGTGGTTCAAAAATGAATTACCATTAACACATGAGACCAAAAAGCTATACATGGTGCCTTATGTGGATTTGGAACACCAAGGAACCTACTGGTGTCATGTATATAATGATCGAGACAGTCAAGATAGCAAGAAGGTAGAAATCATCATAGGAAGAACAGATGAGGCAGTGGAGTGCACTGAAGATGAATTAAATAATCTTGGTCATCCTGATAATAAAGAGCAAACAACTGACCAGCCTTTGGCGAAGGACAAGGTTGCCCTTTTGATAGGAAATATGAATTACCGGGAGCACCCCAAGCTCAAAGCTCCTTTGGTGGATGTGTACGAATTGACTAACTTACTGAGACAGCTGGACTTCAAAGTGGTTTCACTGTTGGATCTTACTGAATATGAGATGCGTAATGCTGTGGATGAGTTTTTACTCCTTTTAGACAAGGGAGTATATGGGTTATTATATTATGCAGGACATGGTTATGAAAATTTTGGGAACAGCTTCATGGTCCCCGTTGATGCTCCAAATCCATATAGGTCTGAAAATTGTCTGTGTGTACAAAATATACTGAAATTGATGCAAGAAAAAGAAACTGGACTTAATGTGTTCTTATTGGATATGTGTAGGAAAAGAAATGACTACGATGATACCATTCCAATCTTGGATGCACTAAAAGTCACCGCCAATATTGTGTTTGGATATGCCACGTGTCAAGGAGCAGAAGCTTTTGAAATCCAGCATTCTGGATTGGCAAATGGAATCTTTATGAAATTTTTAAAAGACAGATTATTAGAAGATAAGAAAATCACTGTGTTACTGGATGAAGTTGCAGAAGATATGGGTAAGTGTCACCTTACCAAAGGCAAACAGGCTCTAGAGATTCGAAGTAGTTTATCTGAGAAGAGAGCACTTACTGATCCAATACAGGGAACAGAATATTCTGCTGAATCTCTTGTGCGGAATCTACAGTGGGCCAAGGCTCATGAACTTCCAGAAAGTATGTGTCTTAAGTTTGACTGTGGTGTTCAGATTCAATTAGGATTTGCAGCTGAGTTTTCCAATGTCATGATCATCTATACAAGTATAGTTTACAAACCACCGGAGATAATAATGTGTGATGCCTACGTTACTGATTTTCCACTTGATCTAGATATTGATCCAAAAGATGCAAATAAAGGCACACCTGAAGAAACTGGCAGCTACTTGGTATCAAAGGATCTTCCCAAGCATTGCCTCTATACCAGACTCAGTTCACTGCAAAAATTAAAGGAACATCTAGTCTTCACAGTATGTTTATCATATCAGTACTCAGGATTGGAAGATACTGTAGAGGACAAGCAGGAAGTGAATGTTGGGAAACCTCTCATTGCTAAATTAGACATGCATCGAGGTTTGGGAAGGAAGACTTGCTTTCAAACTTGTCTTATGTCTAATGGTCCTTACCAGAGTTCTGCAGCCACCTCAGGAGGAGCAGGGCATTATCACTCATTGCAAGACCCATTCCATGGTGTTTACCATTCACATCCTGGTAATCCAAGTAATGTTACACCAGCAGATAGCTGTCATTGCAGCCGGACTCCAGATGCATTTATTTCAAGTTTCGCTCACCATGCTTCATGTCATTTTAGTAGAAGTAATGTGCCAGTAGAGACAACTGATGAAATACCATTTAGTTTCTCTGACAGGCTCAGAATTTCTGAAAAATGACCTCCTTGTTTTTGAAAGTTAGCATAATTTTAGATGCCTGTGAAATAGTACTGCACTTACATAAAGTGAGACATTGTGAAAAGGCAAATTTGTATATGTAGAGAAAGAATAGTAGTAACTGTTTCATAGCAAACTTCAGGACTTTGAGATGTTGAAATTACATTATTTAATTACAGACTTCCTCTTTCTAAGATTTTGTGAATTGGTTGAATAGTTCTATACAAATGAAGTATGGAGGTGTGTATGTTTATATGTATATAACAAAATATTTTCATTGTGACCACTCTGAAGTAAGAGCAATGGGAATGGCATTATTGTAGAATAAGTCATTGTATTTTTAACACCAGAAAGAACCTTGCCGATCACCAGGCATAACCTAATTTTATCCATGGAAGAAACACAGAAAGGCATCTAAGTTAGAGCTGGCACCAGAACTGAGACCTCCAGAAATCTATTCCAGTATTTTTTCCACTACACAACTGCCTTCCTGACAGGTTCTGAGATAAGTGTTATGTTTGTAGATAGAGTGAAATATATTTATATATATATAAATATATACAGATACATATCTGTGTATTATCTCAAGGAATGTACAAACTTTAGTTTTTGATTATAAGGACTTCACTGCAAGTTTTAGTTAAGAGGTTTGTATATAAATCTGTTATAGAACAGGCTGAAATTTCTTGTTCATAAGATTATGAAACCACATGAGAAGTGATAAAATGTTTGTTAAAGCTAGATAGAGGTTAAGAATCAAGATATAATGGATAATTTTCATAGCTGCCTATCAGAATTTCCCAAATATTTAGCATCTTCCTTGATAATATGTATTTTCTTCTTGAATTTCACTGGCCTAATGAGATAATACTCTTATCTTTGGCTCTACCTAAAAGTTGGTTAAAAATGCAATTGGCATTAACAAGGAAAAATACTGAATTAGTAATTTTAAAAGTCTCACAAAGAAAATCCCAGGCCTAGATGGCTGCATTGTTGAATTCTGCCAAACATTAAAATTAGCACTAATTTTTTGCACACTGTTTCTAAAAGTAGGAGAGGAAAGAACACTTCCCAACTTACTCTAGGTCAGTATTACCCTGATACTAGACTAGACATCACAAGAAAACTATAAGCCAATATTCCTTATTAATACAAACACAAAAATCATTAACAAAAATATTAGCAAACTGAATCCAGCAACCTATAAAAAGGATTCTATATCATGACCAAGTGGAATTTATCCCAGGAATTCAAGGTTGGTTCAACATCTAAAAATCAAATAAGCTAATATACAGTCAGTTCTCATTATTCACAGTAATTATGTTCTACAGAATATTCTCCCATAAACACTGAATTAAATATGGAACAACTGCTTTTAGGAGAAAGTGTATTTGTGTATATGTGTGTATACATATGTTTATCTCACACACATTATGAGCTTGAATTCTTAATTCATCCTAGCAAATTCTACCTTATTTTACAGAAGTGAAAGTGAGGTATCAGAAGTGTTAAGTGACATGCCTGAGGCACCCCCCTAACAGGTGTCAGAGCTGAAATTCAAACCCCATCCAGCTGGCCCCGGAGCCAGAGCTTCTTGTACTACACAGAATTGCCCCTGCCATTTCCACCCTCCAGTCATTTCTCTATGAGACTGAAGCAGGAAGGCAGAGCATCATCTTGTTCAGCCTCAGCTGGGAACATGTGTACTGGGTGACTCAAATTTTTCACCCATTTACACATATCCACAAATGACTGCAAAAGTGCCACGGATATCAATTTGAGGGTTATAAATTTTAGCAAGTTGGTAAATTCACAAATACATAACCTTGAATAATGAGGATCAACTGTACCATATTTAATAAAGCACAAAACCCACACAGATTGTCTTATTACAGCATTTGATAAAATCCAAAACTCTTTCATAAAAACACTCAACAAACTTAGGAATAAAAGGAATCTTCCTAGATATGATAAATATAACATCTATGAAAAGCCCACACCTAACATTATACTTCATGGTGATAGACTGAAGGCTGAATGTTTTCCCCTTAAGATTGGGAAGAAGGACAAGGATGTTCACTCGGCACTACTTCTATTCAGCATTGTACTTGAAGTTCTAGCCACAGCAGTTAGGTTAGGAATTCAAGGTTTGTTCAACATCTAAAAATCAAATAAGCTAATAAAGAAAAGAGGTTTATACTGCAAAAGAAGTGAAACTATATGTATTCACAGTTGATACATAGTTGTATATAGAAAATGCTAAAGAATCCATAAAAAGTAATAAATGAGTTCAACAGGTTAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Bone marrow</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Lymph node</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Thymus</TissueLocal>
    </TissueLocal>
    <TissueLocal>
      <TissueLocal>Peripheral blood mononuclear cell</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>CBM complex</CellLocal>
      <Ontology_ID>GO:0032449</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Perinuclear region of cytoplasm</CellLocal>
      <Ontology_ID>GO:0048471</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytosol</CellLocal>
      <Ontology_ID>GO:0005829</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>MALT1</Gene_Name>
    <Gene_Alias>MLT</Gene_Alias>
    <Gene_ID>10892</Gene_ID>
    <Genbank_ACCN>NM_006785</Genbank_ACCN>
    <Protein_ACCN>NP_006776</Protein_ACCN>
    <HGNC_ID>6819</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/10892</Gene_URL>
    <UCSC_ID>uc002lhm.1</UCSC_ID>
    <EMBL_ID>ENSG00000172175</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q13501</Uniprot_ID>
      <Gene_Name>SQSTM1</Gene_Name>
      <EBI_ID>EBI-307104</EBI_ID>
      <PPI_EBI_URL>EBI-1047372,EBI-307104</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9Y6K9</Uniprot_ID>
      <Gene_Name>IKBKG</Gene_Name>
      <EBI_ID>EBI-81279</EBI_ID>
      <PPI_EBI_URL>EBI-1047372,EBI-81279</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O95999</Uniprot_ID>
      <Gene_Name>BCL10</Gene_Name>
      <EBI_ID>EBI-958922</EBI_ID>
      <PPI_EBI_URL>EBI-1047372,EBI-958922</PPI_EBI_URL>
      <Experiment_Number>12</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9Y4K3</Uniprot_ID>
      <Gene_Name>TRAF6</Gene_Name>
      <EBI_ID>EBI-359276</EBI_ID>
      <PPI_EBI_URL>EBI-1047372,EBI-359276</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q14790</Uniprot_ID>
      <Gene_Name>CASP8</Gene_Name>
      <EBI_ID>EBI-78060</EBI_ID>
      <PPI_EBI_URL>EBI-1047372,EBI-78060</PPI_EBI_URL>
      <Experiment_Number>10</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P0CG48</Uniprot_ID>
      <Gene_Name>UBC</Gene_Name>
      <EBI_ID>EBI-3390054</EBI_ID>
      <PPI_EBI_URL>EBI-1047372,EBI-3390054</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Primary Cutaneous Marginal Zone B-Cell Lymphoma</Disease_Name>
      <Disease_Detail>Primary Cutaneous Marginal Zone B-Cell Lymphoma</Disease_Detail>
      <Disease_DB>PRM129</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/primary_cutaneous_marginal_zone_b_cell_lymphoma?search=MALT1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Malt Lymphoma</Disease_Name>
      <Disease_Detail>Malt Lymphoma</Disease_Detail>
      <Disease_DB>MLT022</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/malt_lymphoma?search=MALT1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Marginal Zone B-Cell Lymphoma</Disease_Name>
      <Disease_Detail>Marginal Zone B-Cell Lymphoma</Disease_Detail>
      <Disease_DB>MRG003</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/marginal_zone_b_cell_lymphoma?search=MALT1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Lung Lymphoma</Disease_Name>
      <Disease_Detail>Lung Cancer</Disease_Detail>
      <Disease_DB>LNG013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/lung_lymphoma?search=MALT1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Immunodeficiency 12</Disease_Name>
      <Disease_Detail>Immunodeficiency</Disease_Detail>
      <Disease_DB>IMM071</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/immunodeficiency_12?search=MALT1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gastric Lymphoma</Disease_Name>
      <Disease_Detail>Gastric Lymphoma</Disease_Detail>
      <Disease_DB>GST027</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gastric_lymphoma?search=MALT1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Gallbladder Lymphoma</Disease_Name>
      <Disease_Detail>Gallbladder Cancer</Disease_Detail>
      <Disease_DB>GLL013</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/gallbladder_lymphoma?search=MALT1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Splenic Marginal Zone Lymphoma</Disease_Name>
      <Disease_Detail>Splenic Marginal Zone Lymphoma</Disease_Detail>
      <Disease_DB>SPL004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/splenic_marginal_zone_lymphoma?search=MALT1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diffuse Large B-Cell Lymphoma</Disease_Name>
      <Disease_Detail>Diffuse Large B-Cell Lymphoma</Disease_Detail>
      <Disease_DB>DFF005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diffuse_large_b_cell_lymphoma?search=MALT1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Edwards Syndrome</Disease_Name>
      <Disease_Detail>Edwards Syndrome</Disease_Detail>
      <Disease_DB>EDW001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/edwards_syndrome?search=MALT1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of the tandem IG-like C2-type 2 domains of the human mucosa-associated lymphoid tissue lymphoma translocation protein 1</PDB_Title>
      <PDB_ID>3K0W</PDB_ID>
      <Resolution>2.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3K0W</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the Tandem Ig-Like C2-Type 2 Domains of the Human Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the MALT1 paracaspase (P21 form)</PDB_Title>
      <PDB_ID>3UOA</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3UOA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) paracaspase region.</PubMed_Title>
      <Author>Yu, J.W., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2011)108:21004-21009</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22158899?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the MALT1 paracaspase (P1 form)</PDB_Title>
      <PDB_ID>3UO8</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3UO8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of the mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) paracaspase region.</PubMed_Title>
      <Author>Yu, J.W., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2011)108:21004-21009</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22158899?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray structure of the death domain of the human mucosa associated lymphoid tissue lymphoma translocation protein 1</PDB_Title>
      <PDB_ID>2G7R</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G7R</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray structure of the death domain of the human mucosa associated lymphoid tissue lymphoma translocation protein 1</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Ig-like C2-type 2 domain of the human Mucosa-associated lymphoid tissue lymphoma translocation protein 1</PDB_Title>
      <PDB_ID>3BFO</PDB_ID>
      <Resolution>1.15</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BFO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the Ig-like C2-type 2 domain of the human Mucosa-associated lymphoid tissue lymphoma translocation protein 1.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human MALT1 (334-719) in its ligand free form</PDB_Title>
      <PDB_ID>3V55</PDB_ID>
      <Resolution>1.81</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V55</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Determinants of MALT1 Protease Activity.</PubMed_Title>
      <Author>Wiesmann, C., et al.</Author>
      <Journal>J.Mol.Biol.(2012)419:4-21</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22366302?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human MALT1 (caspase-IG3) in complex with thioridazine</PDB_Title>
      <PDB_ID>4I1R</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I1R</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11010001</ASD_Ligand>
      <PubMed_Title>Structural Analysis of Phenothiazine Derivatives as Allosteric Inhibitors of the MALT1 Paracaspase.</PubMed_Title>
      <Author>Schlauderer, F., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2013)52:10384-10387</Journal>
      <PubMed_ID>23946259</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human MALT1 (caspase domain) in complex with an irreversible peptidic inhibitor</PDB_Title>
      <PDB_ID>3V4O</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3V4O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Determinants of MALT1 Protease Activity.</PubMed_Title>
      <Author>Wiesmann, C., et al.</Author>
      <Journal>J.Mol.Biol.(2012)419:4-21</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22366302?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04064</Pathway_ID>
      <Pathway_Title>NF-kappa B signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05152</Pathway_ID>
      <Pathway_Title>Tuberculosis</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Infectious diseases</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04662</Pathway_ID>
      <Pathway_Title>B cell receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04660</Pathway_ID>
      <Pathway_Title>T cell receptor signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Immune system</Pathway_Subclass>
    </Network>
  </Network_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.4.22.-</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/4/22/-.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD11010001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2013-11-12</Create_Date>
</Organism_Record>